If you bought shares of Altimmune, (NASDAQ: ALT) Vaxart, (NASDAQ: VXRT) or Novavax (NASDAQ: NVAX) at the start of this year, you're already well on your way to riches. Thanks to the market's coronavirus vaccine frenzy, each of these companies' stock prices has exploded by more than 1,000% since the start of the year. But if you didn't invest early on, that's not surprising: Before the pandemic, these biotechs weren't exactly hot stocks.
In fact, none of them had a single drug or vaccine product approved for sale. Initiating COVID-19 vaccine programs was enough to propel them into the market's limelight, but each traveled a slightly different path to reach their current heights. Are any of them still good buys today?
Image source: Getty Images.